SCHEMBL4201295

SCHEMBL4201295

CN(C)C(=O)c1ccc2c(n1)CCN(C(=O)O)CC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.37
GRM5 P41594 5/20 0.37
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NLRP3 Q96P20 1/20 0.33
F10 P00742 1/20 0.32
CNR2 P34972 1/20 0.32
NOTUM Q6P988 1/20 0.32
PIK3CB P42338 1/20 0.32
RIPK1 Q13546 1/20 0.32
KCNH2 Q12809 2/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
BCL2 P10415 1/20 0.31
DRD2 P14416 1/20 0.31
ENPP2 Q13822 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13568076 0.82 ESR2 (0.47) GRM5NPC1RAB9A
SCHEMBL4203495 0.82 GRM5 (0.38) GRM5F10CNR2NOTUMRIPK1
SCHEMBL4011215 0.79 GRM5 (0.36) GRM5MEN1KMT2ANOTUMENPP2
SCHEMBL4206385 0.77 NOTUM (0.34) GRM5KDM4EMEN1KMT2ANLRP3
SCHEMBL288301 0.76 KDM4A (0.38) KDM4AALDH1A1MEN1KMT2ACNR2
SCHEMBL4214604 0.76 HSP90AA1 (0.33) GRM5KDM4EALDH1A1MEN1KMT2A
SCHEMBL4209564 0.75 HTR2C (0.37) KDM4AALDH1A1F10
SCHEMBL28935833 0.75 GRM5 (0.37) GRM5MEN1KMT2ANOTUMGABRG2
SCHEMBL4208644 0.74 NOTUM (0.36) GRM5KDM4EMEN1KMT2ANOTUM
SCHEMBL4008920 0.74 GRM5 (0.53) GRM5KDM4EMEN1KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
EP-2094695-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS Cascade Therapeutics Inc. (CA) 2009-09-02 EP disclosed
WO-2008009125-A9 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS NPS ALLELIX CORP (CA) 2008-07-24 WO disclosed
WO-2008009125-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS HTR2C, HTR2A, HTR5A KDM4A 3788/4885GRM5 25/4885KDM4E 2942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.